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Revealing the mechanisms of protein 
disorder and N-glycosylation in 
CD44-hyaluronan binding using 
molecular simulation
Olgun Guvench*
Department of Pharmaceutical Sciences, University of New England College of Pharmacy, Portland, ME, USA
The extracellular N-terminal hyaluronan binding domain (HABD) of CD44 is a small globular 
domain that confers hyaluronan (HA) binding functionality to this large transmembrane 
glycoprotein. When recombinantly expressed by itself, HABD exists as a globular water-sol-
uble protein that retains the capacity to bind HA. This has enabled atomic-resolution 
structural biology experiments that have revealed the structure of HABD and its binding 
mode with oligomeric HA. Such experiments have also pointed to an order-to-disorder 
transition in HABD that is associated with HA binding. However, it had remained unclear 
how this structural transition was involved in binding since it occurs in a region of HABD 
distant from the HA-binding site. Furthermore, HABD is known to be N-glycosylated, 
and such glycosylation can diminish HA binding when the associated N-glycans are 
capped with sialic acid residues. The intrinsic flexibility of disordered proteins and of 
N-glycans makes it difficult to apply experimental structural biology approaches to probe 
the molecular mechanisms of how the order-to-disorder transition and N-glycosylation 
can modulate HA binding by HABD. We review recent results from molecular dynamics 
simulations that provide atomic-resolution mechanistic understanding of such modulation 
to help bridge gaps between existing experimental binding and structural biology data. 
Findings from these simulations include: Tyr42 may function as a molecular switch that 
converts the HA-binding site from a low affinity to a high affinity state; in the partially 
disordered form of HABD, basic amino acids in the C-terminal region can gain sufficient 
mobility to form direct contacts with bound HA to further stabilize binding; and terminal 
sialic acids on covalently attached N-glycans can form charge-paired hydrogen bonding 
interactions with basic amino acids that could otherwise bind to HA, thereby blocking HA 
binding to glycosylated CD44 HABD.
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introduction
The structure of the cell surface protein CD44, from its N-terminus to its C-terminus, consists 
of a globular hyaluronan binding domain (HABD), a stalk domain, a single-pass transmembrane 
domain, and a cytoplasmic domain (1, 2). Amino acids located N-terminal to the transmembrane 
domain are on the extracellular side of the cell membrane, and amino acids located C-terminal to the 
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transmembrane domain are on the intracellular side (Figure 1). 
Post-translational modifications to CD44 include glycosylation 
of the extracellular portion (3–5), palmitoylation of amino acids 
immediately C-terminal to the transmembrane domain (6–9), 
and phosphorylation of the cytoplasmic domain (10–12). The 
already-complex structural biology of CD44 is further complicated 
by variable splicing of the RNA transcript of the CD44 gene, which 
yields a variety of different patterns of amino acid insertion into 
the stalk domain and which modulates CD44 function (1, 13, 14), 
and by shedding that produces soluble CD44 (15).
Atomic-resolution structures can lead to substantial insight 
into the function of a biomolecule. Such high-resolution structural 
information is typically obtained from X-ray crystallography or 
NMR spectroscopy experiments, with examples being as small as 
a single zinc finger domain (16) and as large as ribosomes (17) 
and virus capsids (18). However, not all biomolecules are equally 
amenable to having their structures solved by these methods. 
Glycoproteins and proteoglycans are particularly challenging 
because of the difficulty in obtaining pure samples and the inherent 
flexibility of these two types of biomolecules. Sample homogeneity 
is a challenge for glycoproteins and proteoglycans because the car-
bohydrate component results from non-template-based enzymatic 
synthesis, leading to carbohydrate microheterogeneity at a given 
glycosylation site even though the protein component for a given 
FiGURe 1 | CD44 structure. The four different structural/functional regions 
are denoted by different colors, and labels include the number of amino acids 
in each region for the standard splice variant “CD44s.” Results of variation in 
RNA splicing include additional amino acids in the stalk region and loss of 
amino acids composing the cytoplasmic region. Amino acid numbering for 
the human isoform begins with residue 21 because of cleavage of a 
20-residue N-terminal signal peptide.
sample is identical throughout (19). The carbohydrate component 
is also flexible (20, 21), especially in comparison to globular proteins 
with their well-defined tertiary (three-dimensional) structures, 
and which therefore were crystallized early in the development of 
the field of structural biology (22) and still compose the majority 
of publicly available experimental atomic-resolution structures.
In contrast to globular proteins, which exist in an aqueous envi-
ronment, transmembrane proteins are located in biological lipid 
bilayers. Therefore, this environment must be suitably reproduced 
in samples in order to do experimental structural biology, which 
can be very challenging (23, 24). Additionally, heterologous expres-
sion of transmembrane proteins and subsequent purification can 
be more difficult than for water-soluble globular proteins because 
of the limited surface area of the cell membrane for expression, 
the resulting toxicity to the organism being used for expression, 
and the subsequent need to reconstitute the protein in a lipid 
environment after extraction and purification (25, 26).
Intrinsically disordered proteins provide another contrast to 
globular proteins in that the former lack well-defined unique 
stable three-dimensional structures (27–29). In X-ray experiments, 
this results in crystallographic disorder, diffuse scattering, and 
therefore undefined atomic coordinates (30). While NMR has 
been used extensively to study intrinsically disordered proteins, 
solution NMR experiments yield data that represent ensemble 
averages, which can limit understanding of the various discrete 
conformations that such proteins may assume (31).
CD44, with its multiple domains, poses a number of challenges 
for characterization by X-ray crystallography or NMR spectros-
copy. The N-terminal HABD, which is similar to globular proteins, 
is in its biologically relevant form a glycoprotein that has numerous 
glycosylation sites (1). Furthermore, HABD in the presence of 
hyaluronan (HA) has characteristics of an intrinsically disordered 
protein (32, 33). The stalk domain that connects the extracellular 
HABD to the cell membrane has both N- and O-glycosylation sites 
(34). And, with alternative splicing, the stalk domain can have 
proteoglycan characteristics, namely a protein core with glycosa-
minoglycan (GAG) attachments in the form of chondroitin sulfate 
and heparan sulfate (35). Recalling that CD44 is a transmembrane 
protein, in addition to the challenge associated with being located 
in the cell membrane, the transmembrane domain can be post-
translationally modified by the attachment of lipids, which further 
complicates its structural biology since this modification can alter 
its interactions with the membrane bilayer (9, 36, 37). Finally, the 
cytoplasmic domain is likely disordered when not non-covalently 
bound to intracellular adapter proteins (12).
Atomic-resolution experimental structural biology on CD44 
has been largely limited to the ~150 amino acid HABD in its 
non-glycosylated form because of the many specific challenges 
above. X-ray structures for HABD exist for both human and mouse 
isoforms. Human HABD has been reproducibly crystallized in its 
apo form (i.e., not bound to HA, inhibitors, or peptides) (38, 39), as 
well as with unidentified peptide (39) found to be non-covalently 
bound to the face of HABD opposite that of the location of the 
HA-binding site. However, there are no publicly available X-ray 
structures of human HABD complexed with either HA or with 
inhibitors of HA binding. In contrast, mouse HABD has been 
co-crystallized with both oligomeric HA (oHA) (40, 41) and 
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small-molecule inhibitors (40), as well as in its apo form (41). These 
co-crystals reveal the binding mode of HA with HABD, which is 
presumably the same for human HABD given the ~85% sequence 
identity between the two forms, and the 100% sequence identity of 
the HA-binding site (42). NMR structures exist for human HABD, 
both in its apo form (38) and bound to oHA (32). However, unlike 
X-ray structures with HA, NMR structural characterization of the 
bound form lacks atomic coordinates for HA and therefore does 
not provide comprehensive information into the non-covalent 
atomic contacts between HABD and bound HA. All of these 
previous structural biology examples are of CD44 HABD; the 
only non-HABD example of experimental CD44 structure is a 
complex consisting of a nine amino acid long portion of the 72 
amino acid cytoplasmic domain complexed with the radixin FERM 
domain (12).
Molecular dynamics (MD) is a physics-based approach to 
the modeling and simulation of biomolecules (43). In all-atom 
explicit-solvent MD simulations, all the atoms of the system, 
including those for the solvent, are included as interaction sites 
for computing the forces in the system. The values of the forces as 
a function of atomic positions are determined by a combination 
of a mathematical expression and parameters, commonly called a 
“force field,” that encodes properties such as the energetic cost to 
stretch a bond or the energetic benefit of a van der Waals or charge-
pairing interaction (44). These forces are numerically integrated 
to propagate the system, and this is done in an iterative manner 
to generate a trajectory, analogous to a movie, that shows how the 
positions of the atoms in the system evolve with the passing of time 
(45). Typical present-day simulations involve tens of thousands 
to hundreds of thousands of atoms with trajectory lengths of tens 
to hundreds of nanoseconds, which require tens to hundreds of 
millions of consecutive integration steps. MD simulations can 
be used to determine not only the time-evolution (dynamics) of 
the system but also the relative probabilities, and therefore free 
energies, associated with different states (thermodynamics) (46). 
As such, MD is an especially useful tool for studying flexible 
biomolecules at an atomic level of resolution, which makes it an 
ideal complement to experimental structural biology techniques 
like X-ray crystallography and NMR spectroscopy (47).
Over the past several years, our research group has applied all-
atom explicit-solvent MD simulations to extend the understanding 
of the function of the CD44 HABD. These efforts have aimed to 
address the following scientific questions: (1) what is the mecha-
nism and associated thermodynamics of a conformational change 
in an arginine-containing loop at the HABD binding site that is 
associated with HA binding? (41); (2) why does HABD transition 
from a well-ordered (folded) three-dimensional structure to one 
that is partially disordered when it binds to HA? (32, 33, 48); and 
(3) why do covalently attached sialyated N-glycans inhibit HA 
binding while unsialyated ones do not? (49–51) This article reviews 
the contribution MD simulations have made toward developing 
answers to these questions. We note that others have also recently 
applied MD simulation to the study of CD44 HABD, with topics 
including conformational flexibility and the microscopic struc-
ture and dynamics of water surrounding HABD (52, 53), and 
the mechanism and thermodynamics of the ordered to partially 
disordered transition (54).
Conformational Switching at the CD44 
HABD Binding Site
Two lines of experimental evidence lead to the hypothesis that 
direct contact between CD44 Arg 41 and HA is a major source 
of binding affinity (“Arg41” reflects amino acid numbering in 
the human form of CD44; the equivalent amino acid is Arg45 
is the mouse form. For simplicity, the human numbering will be 
used throughout this text.). From X-ray crystallography, Arg41 
and the loop that contains it change conformation depending 
upon binding of oHA. In the apo form, the loop is in an open 
conformation that locates this sidechain too far away to contact 
oHA if it were present, and HABD is said to be in the “A” state (38, 
41). In the complexed form, the loop can be either in the open 
conformation, or in a closed conformation that facilitates direct 
contact between the positively charged guanidinium group of the 
Arg41 sidechain and bound oHA, in which case HABD is in the 
“B” state (40, 41) (Figure 2, bottom row). From mutation data, the 
Arg41Ala single point mutation essentially destroys the ability of 
HABD to associate with oHA (41, 55, 56). This thermodynamic 
information demonstrates the critical nature of Arg41 in binding. 
However, the X-ray crystallographic data do not say anything 
about the thermodynamics of the A and B states, other than they 
are both sufficiently stable to be trapped as crystals when oHA is 
bound. And the mutation data do not provide information about 
the conformation of Arg41 when oHA is bound. We therefore 
applied MD simulations in an attempt to tie these two previous 
findings together.
All-atom explicit-solvent MD simulations can be used to 
determine true thermodynamic free energies for a variety of 
biomolecular processes (46, 57–60). This is because of two reasons: 
(1) a model system under study includes water molecules and 
allows for full conformational flexibility of the included biomol-
ecules, which means both solvent effects and entropic effects 
are explicitly included (that is, not as an approximation, but as 
part of the system under investigation); and (2) there exist exact 
mathematical expressions to determine thermodynamic quantities 
directly from simulation data. One approach to determining the 
free-energy difference between two conformational states x and y 
of a biomolecule from MD simulation is to compute the reversible 
work required to transition the system from state x to state y by 
integrating the measured average force along the transition path 
(61). Since free energy is a thermodynamic state function, it does 
not depend on the actual path used to convert the system from 
state x to state y. However, in practice obtaining good numerical 
convergence as well as plausible biological insight both depend 
upon determining a physically reasonable transition path.
For CD44 HABD, the two states are A, having an open loop 
and the Arg41 sidechain separated from bound oHA, and B, with 
a closed loop and the Arg41 sidechain in direct contact with oHA. 
While a simple distance between Arg41 and oHA can be used to 
discriminate between different conformations of the sidechain, it is 
not immediately obvious that a similarly simple metric can be used 
to discriminate between the open vs. closed loop conformations. In 
an effort to identify such a metric, we first compared the conforma-
tions of the backbone dihedral angles φ, ψ for Arg41 and three 
amino acids on either side: -Lys-Asn-Gly-Arg41-Tyr-Ser-Ile-. This 
FiGURe 2 | Thermodynamics of the transition between the A and B 
states of CD44 HABD. Bottom row: In the A state, the Arg41 sidechain 
(tubes) is not in direct contact with oHA (balls-ands-sticks), whereas in the B 
state, the Arg41-containing loop is in a different conformation that facilitates 
direct contact. r is the distance between the Arg41 sidechain guanidinium 
central Cζ atom and the ether oxygen atom in the glycosidic linkage 
connecting GlcNAc3 to GlcUA4 in the bound oHA. Middle row: 
conformational free energies for the wildtype, ordered (left) and wildtype, 
partially disordered (right) forms of HABD. Free-energy values are in kcal/mol, 
contours are every 1 kcal/mol, and data are from Ref. (42). Top row: ordered 
(left) and partially disordered (right) forms of HABD (ribbons) with bound HA 
(balls-and-sticks).
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revealed a difference in the Tyr42 φ dihedral where in the A state 
φ = −60° and in the B state φ = +60° (62). This was followed by 
MD simulation where force was applied to this dihedral angle to 
gradually convert it from one value of φ to the other. In one case, 
starting from the A state and increasing φ converted the system 
to the B state, not just with respect to the Tyr42 backbone but 
also with respect to the separation distance between Arg41 and 
oHA. In the other case, starting from the B state and decreasing 
φ converted the system to the A state, including breaking of the 
contact between Arg41 and oHA. In neither case was any force 
applied to directly affect the Arg41 to oHA distance; rather, changes 
in this distance spontaneously resulted from changes in the loop 
backbone conformation. Furthermore, a similar effect could not 
be achieved using the backbones of other amino acids in the loop 
(62). Thus, the reaction path for interconversion between the A 
and B states was defined in terms of two progress variables: the 
value of the Tyr42 backbone dihedral angle φ, and the distance r 
between the Arg41 sidechain guanidinium central Cζ atom and the 
ether oxygen atom in the glycosidic linkage connecting GlcNAc3 
to GlcUA4 in the bound oHA.
Extensive simulations were subsequently done to compute the 
free energy of the system as a function of the progress variables φ 
and r (42). All simulations were of the human HABD (hHABD) 
complexed with [-4GlcUAβ1-3GlcNAcβ1-]4 (“HA8”), which was 
computationally constructed by combining information from 
mouse and human structures. The four hHABD-HA8 systems 
considered were: wildtype, ordered; wildtype, partially disordered; 
Arg41Ala, ordered; and Arg41Ala, partially disordered. Figure 2, 
middle row shows the data for both wildtype systems, and the 
major free-energy minima, which are the most stable states for 
each system, correspond to A and B.
Wildtype simulation data demonstrate that the B state of 
the hHABD-HA8 complex is more stable than the A state by 
~8–9  kcal/mol. This is true for both the ordered and partially 
disordered forms of hHABD (Figure  2, top row). Additional 
simulation data demonstrate that the analogous transition for 
the Arg41Ala mutant is substantially less favorable at ~6 kcal/
mol. From these data, it is possible to calculate the loss in bind-
ing affinity associated with the point mutation, with values of 
2.2 kcal/mol for the ordered form and 2.3 kcal/mol for the partially 
disordered form (42). These simulation data are in close agreement 
with existing experimental data measuring the loss in binding 
affinity to be 2.5 kcal/mol (41), which helps validate both the force 
field and the convergence of the simulations. Taken together, these 
results support the idea that formation of direct contact between 
HA and the Arg41 sidechain is a substantial source of favorable 
binding free energy (41).
In contrast to some of these findings, Plazinski and Knys-
Dzieciuch, in their simulation studies, found that the φ-related free-
energy barrier was not correlated with the Arg41-HA distance (54, 
63). The authors also observed a low free-energy barrier associated 
with separation of Arg41 from HA, with the A and B states reducing 
to an average dynamic structure (54, 63). They suggested that a 
possible explanation might be differences in the force fields used 
in their studies (54), since the previous analogous work found the 
A and B states to be distinct (62). Differences in force fields, which 
are the underlying physical models used to represent the bonded 
and non-bonded interactions in such simulations, can indeed cause 
such differing results. When such differences are inferred based on 
differing simulation results and conclusions, one possibility is to 
review the methodology involved in the force field development 
(44, 64). Another is to compare the outcomes of the particular 
simulations with the existing experimental data for inconsisten-
cies. In this particular case, relevant experimental data include 
the crystal structures of the A and B states of HABD complexed 
with oHA, and the mutation data showing loss of binding affinity 
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in the Arg41Ala mutant. Dynamic averaging would manifest as 
crystallographic disorder with poorly resolved electron density for 
Arg41, which is in contrast to the existing crystallographic data. 
Additionally, rapid equilibrium between short and long separation 
distances between Arg41 and oHA suggests a weak interaction 
between them, which is in contrast to the mutation data.
Binding and Unfolding in CD44 HABD
Early experimental studies of the Arg41Ala mutation that predated 
the CD44 structural studies also probed the contribution of other 
basic amino acids by both point and truncation mutations (55). 
This was a logical course of action in the absence of HABD three-
dimensional structure since HA contains a negatively charged 
carboxylate group every other monosaccharide and Arg and Lys 
sidechains are positively charged, suggesting the possibility of 
charge-charge interaction as a mechanism of binding. From that 
perspective, it is not surprising that these mutations all decrease the 
strength of binding of HA oligomers. But, taken in the context of 
the subsequent structural information, the explanation is less obvi-
ous, since these additional amino acids, in contrast to Arg41, are 
located spatially far from the now-known binding site (41). Further 
complicating the situation is the observation that the portion of 
HABD that contains these amino acids 153-169 goes from having 
well-defined three-dimensional structure to becoming unfolded in 
conjunction with HA binding (32, 33, 48). That is, the change in the 
conformation, which correlates with the binding of HA, in this span 
of amino acids located in the C-terminal most region of HABD is 
what defines the ordered-to-partially disordered HABD transition.
The above suggests two questions: why do basic amino acids 
distant from the binding site affect affinity? And why is the affinity 
greater when the sequence containing these amino acids unfolds 
and becomes disordered? To answer these two questions, we return 
to the previous set of free-energy data from MD simulations. 
For wildtype hHABD, the free-energy data associated with the 
interconversion between the A and B states are qualitatively the 
same regardless of whether hHABD is in the ordered or partially 
disordered form (Figure  2, middle row). The same is also the 
case for the Arg41Ala mutant, where the free-energy change in 
going from A to B is independent of whether those distant amino 
acids are folded or not (42) (data not shown here). Not only are 
there strong qualitative similarities in free-energy data between 
the ordered and partially disordered forms, but the quantitative 
values are also very similar. For the A→B transition of the bind-
ing site in the wildtype, ordered form, the associated free-energy 
change is −8.7 kcal/mol, and for this transition in the wildtype, 
partially disordered form the value is a very similar −7.8 kcal/
mol (42). Likewise for the Arg41Ala mutant, in the ordered form 
the value is −6.5 kcal/mol and in the partially disordered form 
it is −5.5 kcal/mol (42). The small difference of ~1 kcal/mol is 
within the precision that can be expected from these particular 
computational experiments.
In an allosteric mechanism, a conformational change distant 
from the site affects the energetics at the binding site. In the case 
of HABD, the independence of the energetics of the binding site 
A→B transition from the ordered vs. partially disordered form of 
HABD contradicts the hypothesis that allostery is at work. That is, 
conformational switching at the binding site appears no more or 
less favorable if the HABD C-terminal region is folded or unfolded.
Analysis of the MD trajectories that were generated as part of 
the free-energy experiments yielded a result that, in hindsight, 
is obvious: flexibility from partial unfolding permits favorable 
electrostatic interactions between HA and the C-terminal HABD 
amino acids that cannot occur when the domain is fully ordered. 
In the ordered form of HABD, the amino acids in question are 
locked into a folded conformation that keeps them far from bound 
oHA, while in the partially disordered form, this is no longer the 
case (Figure 2, top row). Because this span of amino acids is no 
longer in consistent contact with the rest of the HABD domain, it 
assumes the properties of a random coil peptide, which through 
random fluctuations can collide with bound oHA. If this collision 
happens in a way that brings one of the basic sidechains into close 
proximity with oHA, a favorable contact can be formed. Unlike 
the Arg41 interaction, which has a well-defined mechanism based 
on specific interactions of the sidechain with a particular limited 
section of bound oHA, the flexibility of the disordered amino acids 
and the repeating nature of the HA polymer permit the possibility 
of a wide range of basic sidechain interactions with bound HA 
(42), consistent with the long-standing finding that a 13-amino 
acid CD44 peptide spanning Arg150–Arg162 itself will bind HA 
(65). This wide range may conceivably include interaction with 
HA bound to an adjacent molecule of CD44, though the present 
simulations had a single copy of the complex and therefore could 
not directly address the possibility of such trans association.
The above computational experiments do suggest a plausible 
molecular mechanism by which the ordered to partially disordered 
transition confers increased binding affinity to oHA. However, the 
simulations involved either the ordered or the partially disordered 
form of CD44 hHABD, and therefore do not provide any insight 
into the mechanism of the ordered to partially disordered transi-
tion itself. Independent work has been done toward this end, and 
with the additional aims of estimating the free-energy profile of the 
transition and clarifying the role of select amino acids in the transi-
tion (54). Connected with the proposed transition mechanism 
was a free-energy change of +25 kcal/mol, implying the partially 
disordered form in the absence of HA is very unstable relative to 
the ordered form. While the sign of the free-energy change, associ-
ated with loss of a single beta strand at the edge of a beta sheet, 
agrees with experiment (32), the magnitude is substantially larger 
than the folding free-energy values for entire small single-domain 
proteins, which are typically <10 kcal/mol, including for proteins 
consisting exclusively of beta strands (66). A further difficulty is 
that the simulation free-energy data for the analogous transition in 
the Tyr161Ala mutant are identical to those for the wild type. This 
is in contrast to experimental data, where the Tyr161Ala mutant 
constitutively exhibits the partially disordered conformation (33, 
48). One possible explanation for these apparent inconsistencies 
is that the study represents the initial steps of the transition (54), 
such that extending simulations further along the selected reac-
tion coordinate may result in subsequent decreases in free energy. 
Another possibility is lack of convergence of simulations given 
the large scale of the transition (54). This was the case for the free 
energy for the A→B transition, which involves a much smaller 
conformational change than the ordered to partially disordered 
FiGURe 3 | Molecular dynamics snapshots demonstrating ordered 
HABD (ribbons) residue Arg41 (van der waals spheres) forming a 
charge-paired hydrogen bonding interaction with complex-type 
N-glycan (balls-and-sticks; sialic acid atoms in purple) attached to 
Asn25. Data are timepoints from a single 100-nanosecond (ns) trajectory 
from Ref. (70).
June 2015 | Volume 6 | Article 3056
Guvench CD44 molecular simulation
Frontiers in Immunology | www.frontiersin.org
transition. The first study suggested that the A and the B states 
were essentially equally stable (62), while subsequent work that 
extended the timescale of the simulations by 40-fold showed the B 
state to be substantially more stable than the A (42). Importantly, 
in the case of the ordered to partially disordered transition, the 
partially disordered form is not a single, well-defined conforma-
tion. Rather, the disordered C-terminal HABD amino acids are free 
to take on a multitude of conformations. Therefore the partially 
disordered form is actually an ensemble of diverse conformations, 
and this further complicates computational experiments toward 
understanding the transition mechanism.
inhibition by Glycosylation
N-glycosylation of CD44 HABD is known to have variable effects 
on CD44 function depending on the nature of the N-glycans. 
One effect is to block HABD binding to HA (49–51). Another 
is to make CD44 itself a ligand that binds to lectins (67, 68). 
The biochemistry behind both of these contrasting functions is 
related and is modulated by N-acetylneuraminic acid (Neu5Ac) 
monosaccharide, which is commonly called “sialic acid.” In one 
case, HABD N-glycans are capped with sialic acids, and this both 
blocks HA binding and makes CD44 a selectin ligand. In the other 
case, sialidase activity removes these terminal sialic acids, leaving 
the bulk of the N-glycan structures intact, and this change restores 
both HA-binding and removes selectin ligand functionality. While 
sialidase treatment removes only the terminal monosaccharide 
from the attached N-glycan, the functional result is the same as 
removal of the entire N-glycan. For example, Asn point mutation 
precludes N-glycan attachment and heterologous expression yields 
non-glycosylated protein. In both of these cases, the functional 
outcome is the same as sialidase treatment, which implies that 
inhibition of HA-binding cannot be explained as a consequence 
of steric blockage of the HABD binding site, since the de-sialylated 
N-glycan has nearly the same bulk as the sialo-glycan. This 
mechanism of regulation is not unique to CD44, as the related 
hyaladherin LYVE-1 demonstrates similar behavior (69).
The sialidase data immediately suggest two sets of simulations 
of glycosylated HABD: one set with sialylated N-glycan and a 
second set with asialo N-glycan. Asn25 and Asn120 were selected 
for computational N-glycosylation based on previous mutagenesis 
studies showing that cells expressing Asn25Ser and Asn120Ser 
mutants constitutively bind HA (50). Complex-type N-glycans that 
were selected (70) based on the existing finding that blocking the 
metabolic pathway for processing complex N-glycans restores HA 
binding (71, 72). In conjunction with the two different glycosyla-
tion sites and the sialo and asialo forms of the N-glycan, both 
the ordered and partially disordered forms of CD44 HABD were 
studied in the simulations. A representative starting conformation 
of ordered HABD with a sialo glycan attached to Asn25 is shown 
in the left frame of Figure 3; the analogous asialo form would be 
missing only the atoms colored purple.
The key finding from the comprehensive set of simulations 
covering the ordered and disordered HABD paired with sialo 
and asialo N-glycans is that only in the sialo form do stable, 
long-lasting non-covalent contacts form between the protein 
and glycan components. Furthermore, these contacts involve 
the positively charged sidechains of HABD amino acids and the 
negatively charged carboxylate groups of the terminal sialic acids 
(Figure 3). In contrast, asialo glycans form only brief contacts, 
which is understandable since they lack the negative charge of the 
sialo form. Long-lasting contacts in the sialoglycan simulations 
involve Arg41 and Arg154, and these contacts form spontaneously 
during the simulation and can last for 40–50% of the simulation 
length (70). Both of these amino acids can directly associate with 
HA8 when it is bound, based on findings from the computational 
experiments on partially disordered HABD, as summarized in 
the previous section. However, their binding with sialic acid is an 
interaction that would directly compete with their binding with 
HA8. Therefore, the view that emerges is that, in the sialo form, the 
covalently attached N-glycans will form charge-paired hydrogen 
bonding interactions with Arg sidechains known to be important 
for HA binding. As further evidence, free-energy simulations, 
similar to the ones for Arg41–HA8 association described in the 
previous section, demonstrate that the Arg–sialic acid association 
is indeed thermodynamically favorable by ~1 kcal/mol (70). We do 
note that these simulations were limited to only the CD44 HABD, 
which is present in all splice variants of CD44, and that the simula-
tions did not include HA. Clearly, additional work needs to be done 
to understand the molecular mechanisms by which glycosylation 
alters binding, since it has been shown that N-glycosylation of 
CD44 can also facilitate HA binding (73).
Conclusion
A subset of the computational experiments above suggests the 
following four conclusions. The first is that the Tyr42 backbone 
dihedral angle φ can act as a molecular switch to convert the 
HABD HA-binding site from the open A state to the closed B 
state, which includes the formation of direct contact between HA 
and the Arg41 sidechain (62). The second is that the B state is 
more thermodynamically stable, and this stability is due to direct 
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Arg41-HA contact (42). The third is that basic amino acids located 
distant from the HA-binding site in the ordered form of HABD gain 
sufficient mobility in the partially disordered form to be able to form 
direct contacts with oHA and further stabilize binding (42). And the 
fourth is that terminal sialic acids on covalently attached N-glycans 
can form charge-paired hydrogen bonding interactions with basic 
amino acids that could otherwise bind to HA, thereby blocking 
HA binding to glycosylated CD44 HABD (70). In addition to con-
tributing to the mechanistic understanding of CD44-HA binding, 
these conclusions may be of utility in the future development of 
small-molecule modulators of CD44 function (40), especially given 
the potential for CD44 as a therapeutic target (74–76).
However, it should be kept in mind that the role of Tyr42 as 
a molecular switch, and the discrete nature of the A and B states 
of the Arg41-containing loop is contradicted by other computa-
tional work (54, 63) Furthermore, there do exist experimental 
data that are in apparent conflict with the above conclusions. As 
mentioned previously, N-glycosylation of CD44 can facilitate HA 
binding (73). And, mutation of positively charged amino acids 
in the disordered region has been found to enhance HA-binding 
affinity in the context of both purified HABD and cell surface CD44 
(41). Given these differences, further investigation is warranted 
to achieve a comprehensive consistent view. Finally, while outside 
the scope of this review, there have been substantial efforts using 
MD simulations to understand the importance of water molecules 
and of biomolecular conformational entropy changes in HABD 
binding with HA (52, 53). Findings from these simulations that 
can inform development of small-molecule modulators of CD44 
function include reduced translational and rotational freedom of 
water molecules in contact with HABD and HA, and loss of HA 
flexibility associated with binding to HABD.
The concept of doing computational experiments to 
address biological questions is appealing, but the technique 
used here, namely all-atom explicit-solvent MD simulations, 
requires significant resources. The most obvious resource is 
computing capacity, since the computing demands are quite 
large. It is not uncommon for a set of simulations to utilize the 
equivalent of hundreds to thousands of personal computers 
running at full speed around the clock for weeks at a time. In 
practice, this type of computing power tends to be restricted 
to nationally funded supercomputing centers (77). A second 
is the development of software capable of making optimal 
use of modern supercomputers (78–81). And a third is the 
development of accurate models (i.e., force fields) for the 
types of molecules that make up the biological systems under 
study (44, 64, 82). For example, the development of just the 
carbohydrate component of the force field used in our studies 
of CD44 HABD involved a collaborative effort spanning over 
half a decade (83–91). Fortunately, the technique continues 
to mature, resulting in an increasingly reliable analytical 
scientific methodology capable of providing accurate and 
direct insight into questions that could be addressed only 
indirectly and with great technical difficulty using other 
approaches.
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